BeOne Medicines (ONC) Stock Price, News & Analysis

Company Overview

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers. BeOne Medicines also maintains a pipeline of investigational therapies targeting a range of solid tumors and hematologic malignancies.

Founded in 2010, the company serves markets in North America, Europe, Asia and other international regions through its global commercial and clinical-development network. John V. Oyler, the company’s founder, serves as chairman and chief executive officer.

Key Stats

• Today's Range: $386.45 to $405.00
• 50-Day Range: $341.80 to $387.25
• 52-Week Range: $253.95 to $405.00
• Volume: 959,362 shs
• Average Volume: 395,963 shs
• Market Capitalization: $42.52 billion
• P/E Ratio: 68.18
• Dividend Yield: N/A
• Price Target: $424.26
• Consensus Rating: Buy

BeOne Medicines Stock Analysis - MarketRank™

BeOne Medicines scored higher than 80% of companies evaluated by MarketBeat, and ranked 104th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Buy

Consensus Rating

BeOne Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 15 buy ratings, 1 hold rating, and no sell ratings.

Upside/Downside

The consensus price target for BeOne Medicines is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

BeOne Medicines has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 52.50%

Earnings Growth

Earnings for BeOne Medicines are expected to grow by 52.50% in the coming year, from $8.99 to $13.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BeOne Medicines is 68.18, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.10.

Price to Earnings Ratio vs. Sector

The P/E ratio of BeOne Medicines is 68.18, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.38.

Price to Book Value per Share Ratio

BeOne Medicines has a P/B Ratio of 9.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.74% of the float of BeOne Medicines has been sold short.

Short Interest Ratio / Days to Cover

BeOne Medicines has a short interest ratio ("days to cover") of 4.87.

Change versus previous month

Short interest in BeOne Medicines has recently decreased by 7.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BeOne Medicines does not currently pay a dividend.

Dividend Growth

BeOne Medicines does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.98

News Sentiment

BeOne Medicines has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for BeOne Medicines this week, compared to 6 articles on an average week.

Search Interest

Only 5 people have searched for ONC on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

4 people have added BeOne Medicines to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BeOne Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $134,848,154.00 in company stock.

Percentage Held by Insiders

6.19% of the stock of BeOne Medicines is held by insiders.

Percentage Held by Institutions

48.55% of the stock of BeOne Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/05/2026
• Today: 11/06/2026
• Jefferies Global Healthcare Conference: 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ONC
• Previous Symbol: NASDAQ:ONC
• CIK: 1651308
• Web: beonemedicines.com
• Phone: 13459494123
• Fax: N/A
• Employees: 12,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BeOne Medicines: $424.26
• High Price Target: $484.91
• Low Price Target: $367.00
• Potential Upside/Downside: +9.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.68
• Trailing P/E Ratio: 68.18
• Forward P/E Ratio: 28.25
• P/E Growth: N/A
• Net Income: $286.93 million
• Net Margins: 10.70%
• Pretax Margin: 14.16%
• Return on Equity: 14.23%
• Return on Assets: 7.82%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 3.40
• Quick Ratio: 3.06

Sales & Book Value

• Annual Sales: $6.61 billion
• Price / Sales: 6.44
• Cash Flow: $4.01 per share
• Price / Cash Flow: 96.66
• Book Value: $39.77 per share
• Price / Book: 9.74

Miscellaneous

• Outstanding Shares: 109,787,000
• Free Float: 102,991,000
• Market Cap: $42.52 billion
• Optionable: Optionable
• Beta: 0.63